Cargando…
Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia
Upstream mutations that lead to constitutive activation of Erk in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) are relatively common. In the era of personalized medicine, flow cytometry could be used as a rapid method for selection of optimal therapies, which may include drugs that target...
Autores principales: | George, Aswathi A., Paz, Helicia, Fei, Fei, Kirzner, Jonathan, Kim, Yong-mi, Heisterkamp, Nora, Abdel-Azim, Hisham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567297/ https://www.ncbi.nlm.nih.gov/pubmed/26360058 http://dx.doi.org/10.1371/journal.pone.0137917 |
Ejemplares similares
-
Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells
por: Fei, Fei, et al.
Publicado: (2014) -
B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3
por: Fei, Fei, et al.
Publicado: (2015) -
Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008
por: Paz, Helicia, et al.
Publicado: (2018) -
Pre-B acute lymphoblastic leukemia expresses cell surface nucleolin as a 9-O-acetylated sialoglycoprotein
por: Joo, Eun Ji, et al.
Publicado: (2018) -
Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Fei, Fei, et al.
Publicado: (2022)